Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production.
Acetates
/ pharmacology
Animals
Dysbiosis
/ complications
Fatty Acids, Volatile
/ biosynthesis
Feeding Behavior
Gastrointestinal Microbiome
/ drug effects
Gastrointestinal Tract
/ drug effects
Humans
Influenza, Human
/ microbiology
Lung
/ microbiology
Macrophages, Alveolar
/ drug effects
Mice, Inbred C57BL
Pneumococcal Infections
/ complications
Receptors, G-Protein-Coupled
/ agonists
Respiratory Tract Infections
/ microbiology
Superinfection
/ complications
acetate
bacterial superinfection
food restriction
free fatty acid receptor 2
gut microbiota
influenza A virus
macrophages
microbial dysbiosis
short-chain fatty acid
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
03 03 2020
03 03 2020
Historique:
received:
24
09
2019
revised:
13
12
2019
accepted:
04
02
2020
entrez:
5
3
2020
pubmed:
5
3
2020
medline:
25
3
2021
Statut:
ppublish
Résumé
Secondary bacterial infections often complicate viral respiratory infections. We hypothesize that perturbation of the gut microbiota during influenza A virus (IAV) infection might favor respiratory bacterial superinfection. Sublethal infection with influenza transiently alters the composition and fermentative activity of the gut microbiota in mice. These changes are attributed in part to reduced food consumption. Fecal transfer experiments demonstrate that the IAV-conditioned microbiota compromises lung defenses against pneumococcal infection. In mechanistic terms, reduced production of the predominant short-chain fatty acid (SCFA) acetate affects the bactericidal activity of alveolar macrophages. Following treatment with acetate, mice colonized with the IAV-conditioned microbiota display reduced bacterial loads. In the context of influenza infection, acetate supplementation reduces, in a free fatty acid receptor 2 (FFAR2)-dependent manner, local and systemic bacterial loads. This translates into reduced lung pathology and improved survival rates of double-infected mice. Lastly, pharmacological activation of the SCFA receptor FFAR2 during influenza reduces bacterial superinfection.
Identifiants
pubmed: 32130898
pii: S2211-1247(20)30167-4
doi: 10.1016/j.celrep.2020.02.013
pii:
doi:
Substances chimiques
Acetates
0
Fatty Acids, Volatile
0
Ffar2 protein, mouse
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2934-2947.e6Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S000453/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests A.B., V.S., M.M.T., L.P.T., F.T., and A.T.V. are inventors of patent WO2019149727, “Use of short chain fatty acids for the treatment of bacterial superinfections post-influenza.” V.S., T.U., and F.T. are inventors of patent EP19188615.9, “Use of free fatty acid receptor 2 agonists for the treatment of bacterial superinfections post-influenza.”